Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits.
Vaccination of experimental animals can provide efficient protection against ocular herpes simplex virus type 1 (HSV-1) challenge. Although it is suspected that local immune responses are important in protection against ocular HSV-1 infection, no definitive studies have been done to determine if local ocular vaccination would produce more efficacious protection against HSV-1 ocular challenge than systemic vaccination. To address this question, we vaccinated groups of rabbits either systemically or periocularly with recombinant HSV-2 glycoproteins B (gB2) and D (gD2) in MF59 emulsion or with live KOS (a nonneurovirulent strain of HSV-1). Three weeks after the final vaccination, all eyes were challenged with McKrae (a virulent, eye disease-producing strain of HSV-1). Systemic vaccination with either HSV-1 KOS or gB2/gD2 in MF59 did not provide significant protection against any of the four eye disease parameters measured (conjunctivitis, iritis, epithelial keratitis, and corneal clouding). In contrast, periocular vaccination with gB2/gD2 in MF59 provided significant protection against conjunctivitis and iritis, while ocular vaccination with live HSV-1 KOS provided significant protection against all four parameters. Thus, local ocular vaccination provided better protection than systemic vaccination against eye disease following ocular HSV-1 infection. Since local vaccination should produce a stronger local immune response than systemic vaccination, these results suggest that the local ocular immune response is very important in protecting against eye disease due to primary HSV-1 infection. Thus, for clinical protection against primary HSV-1-induced corneal disease, a local ocular vaccine may prove more effective than systemic vaccination.
Nesburn
A B
AB
Ophthalmology Research Laboratories, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Slanina
S
S
Burke
R L
RL
Ghiasi
H
H
Bahri
S
S
Wechsler
S L
SL
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D005123:Eye; D016849:Keratitis, Herpetic / Q000276:immunology / Q000517:prevention & control*; D011136:Polysorbates / Q000008:administration & dosage; D011817:Rabbits; D018139:Simplexvirus / Q000276:immunology; D013185:Squalene / Q000008:administration & dosage; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014765:Viral Vaccines / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; C089950:MF59 oil emulsion; D011136:Polysorbates; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D013185:Squalene